Medtronic Global SYMPLICITY Registry Shows Strong Safety Profile of the Symplicity™ Renal Denervation System

Medtronic, Inc. (NYSE: MDT), announced today further analysis of six-month follow-up data from the first 1,000 patients enrolled in the Global SYMPLICITY Registry, which continue to demonstrate the safety of the Symplicity™ renal denervation system. The results of this observational, open-label study show that renal denervation with the Symplicity™ renal denervation system resulted in significant reductions in both office and 24-hour ambulatory blood pressure compared to baseline, with very low adverse event rates to six months.
Source: News from Angioplasty.Org - Category: Cardiology Source Type: news